1,666 results on '"Guttman-Yassky, Emma"'
Search Results
102. The vIGA‐AD scale for atopic dermatitis: uptake in the past five years and position of the International Eczema Council
103. Efficacy of rocatinlimab for moderate-to-severe atopic dermatitis – Authors' reply
104. Selective JAK1 Inhibitors for the Treatment of Atopic Dermatitis: Focus on Upadacitinib and Abrocitinib
105. Two‐sample Mendelian randomization analysis identifies a causal association between atopic dermatitis and impetigo.
106. Hands-on: a novel JAK inhibitor for the treatment of chronic hand eczema.
107. 627 - A checklist to aid in identifying patients with atopic dermatitis who are candidates for systemic therapy.
108. Selective sweep for an enhancer involucrin allele identifies skin barrier adaptation out of Africa
109. Crisaborole and atopic dermatitis skin biomarkers: An intrapatient randomized trial
110. Author Correction: Neoadjuvant clinical trials provide a window of opportunity for cancer drug discovery
111. Correction to: Qualitative Assessment of Adult Patients’ Perception of Atopic Dermatitis Using Natural Language Processing Analysis in a Cross-Sectional Study
112. Qualitative Assessment of Adult Patients’ Perception of Atopic Dermatitis Using Natural Language Processing Analysis in a Cross-Sectional Study
113. Clinically Meaningful Responses to Dupilumab in Adolescents with Uncontrolled Moderate-to-Severe Atopic Dermatitis: Post-hoc Analyses from a Randomized Clinical Trial
114. Oral Janus kinase/SYK inhibition (ASN002) suppresses inflammation and improves epidermal barrier markers in patients with atopic dermatitis
115. Cutaneous p38 mitogen-activated protein kinase activation triggers psoriatic dermatitis
116. The skin as an immune organ: Tolerance versus effector responses and applications to food allergy and hypersensitivity reactions
117. GBR 830, an anti-OX40, improves skin gene signatures and clinical scores in patients with atopic dermatitis
118. Age-specific changes in the molecular phenotype of patients with moderate-to-severe atopic dermatitis
119. Blood endotyping distinguishes the profile of vitiligo from that of other inflammatory and autoimmune skin diseases
120. A Phase 2 Randomized Trial of Apremilast in Patients with Atopic Dermatitis
121. Report from the National Institute of Allergy and Infectious Diseases workshop on “Atopic dermatitis and the atopic march: Mechanisms and interventions”
122. Ichthyosis molecular fingerprinting shows profound TH17 skewing and a unique barrier genomic signature
123. Human and computational models of atopic dermatitis: A review and perspectives by an expert panel of the International Eczema Council
124. Atopic dermatitis endotypes and implications for targeted therapeutics
125. Dupilumab progressively improves systemic and cutaneous abnormalities in patients with atopic dermatitis
126. Baseline IL-22 expression in patients with atopic dermatitis stratifies tissue responses to fezakinumab
127. Monoclonal antibodies for moderate-to-severe atopic dermatitis: a look at phase III and beyond
128. Clinical and molecular effects of oral CCR4 antagonist RPT193 in atopic dermatitis: A Phase 1 study.
129. The vIGA‐AD scale for atopic dermatitis: Uptake in the past 5 years and position of the International Eczema Council.
130. Transcriptomic Profiling of Tape-Strips From Moderate to Severe Atopic Dermatitis Patients Treated With Dupilumab
131. Dupilumab Significantly Modulates Pain and Discomfort in Patients With Atopic Dermatitis: A Post Hoc Analysis of 5 Randomized Clinical Trials
132. Chronic Hand Eczema Guidelines From an Expert Panel of the International Eczema Council
133. Nomenclature of allergic diseases and hypersensitivity reactions: Adapted to modern needs: An EAACI position paper
134. Association between alopecia areata and atopic dermatitis: A nested case-control study of the All of Us database
135. Treat‐to‐target in dermatology: A scoping review and International Eczema Council survey on the approach in atopic dermatitis
136. Improvements in Immune/Melanocyte Biomarkers With JAK3/TEC Family Kinase Inhibitor Ritlecitinib in Vitiligo
137. Individual and sociodemographic factors associated with polysensitization at a New York City hospital
138. Sclerotic-Type Cutaneous Chronic Graft-Versus-Host Disease Exhibits Activation of T Helper 1 and OX40 Cytokines
139. Upadacitinib treatment withdrawal and retreatment in patients with moderate‐to‐severe atopic dermatitis: Results from a phase 2b, randomized, controlled trial
140. Intrapatient comparison of atopic dermatitis skin transcriptome shows differences between tape‐strips and biopsies
141. Real-world evidence on atopic dermatitis: Baseline characteristics and predictors of treatment choice in the TARGET cohort
142. Pemphigoid and atopy: A case-control study in the All of Us database
143. The Major Orphan Forms of Ichthyosis Are Characterized by Systemic T-Cell Activation and Th-17/Tc-17/Th-22/Tc-22 Polarization in Blood
144. Atopic dermatitis yardstick: Practical recommendations for an evolving therapeutic landscape
145. Immunologic, microbial, and epithelial interactions in atopic dermatitis
146. JAK Inhibitors for Atopic Dermatitis: An Update
147. The Unique Molecular Signatures of Contact Dermatitis and Implications for Treatment
148. A randomized placebo-controlled single-center pilot study of the safety and efficacy of apremilast in subjects with moderate-to-severe alopecia areata
149. Expert Perspectives on Management of Moderate-to-Severe Atopic Dermatitis: A Multidisciplinary Consensus Addressing Current and Emerging Therapies
150. Association between alopecia areata and atopic dermatitis: A nested case-control study of the All of Us database
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.